Krabbe’s disease – Diagnostics – Overview of Information and Clinical Research

Krabbe disease diagnostics involve multiple testing methods that help doctors identify this rare genetic condition, distinguish it from other neurological disorders, and determine the best course of action for affected individuals and their families.

Introduction: Who Should Undergo Diagnostics

Figuring out whether someone has Krabbe disease starts with recognizing when testing is necessary. Parents and healthcare providers should consider diagnostic testing when a baby shows certain worrying signs during the first year of life. These warning signals include extreme fussiness that doesn’t improve with typical comfort measures, unusual muscle stiffness or weakness, difficulty feeding, unexplained fevers without any infection, and the loss of developmental milestones that the baby had previously achieved, such as smiling, reaching for objects, or holding their head up.^[1]

Some babies may be identified before they show any symptoms through newborn screening, which is a test performed shortly after birth to detect serious health conditions. However, not all states or countries include Krabbe disease in their newborn screening programs, which means many children are only diagnosed after symptoms appear.^[6] When a baby receives a positive result from newborn screening, additional testing should be done urgently to confirm whether Krabbe disease is actually present and how quickly it might progress.

For families who already have a child with Krabbe disease, testing becomes particularly important for future pregnancies. Parents who are carriers—meaning they have one abnormal copy of the gene but don’t have symptoms themselves—have a 25% chance with each pregnancy of having a child affected by Krabbe disease.^[6] In these situations, testing during pregnancy or shortly after birth can help families prepare for the care their child may need.

Older children, teenagers, and adults may also need diagnostic testing if they develop symptoms that suggest Krabbe disease. These later-onset forms typically start with vision problems, difficulty walking, progressive muscle weakness, or cognitive changes. Because these symptoms can overlap with many other conditions, thorough diagnostic testing is essential to identify Krabbe disease accurately.^[1]

⚠️ Important

Early diagnosis is crucial for babies suspected of having Krabbe disease. Research shows that medical interventions offered to babies before they develop symptoms tend to have better outcomes than treatment started after symptoms appear. If your baby receives a positive newborn screening result for Krabbe disease, follow up with your pediatrician, a genetic counselor, or a Krabbe disease specialist immediately.^[6]

Classic Diagnostic Methods

Once a doctor suspects Krabbe disease based on symptoms or screening results, several diagnostic methods help confirm the diagnosis and rule out other conditions that might cause similar problems.

Enzyme Activity Testing

The most definitive way to diagnose Krabbe disease is by measuring the activity of an enzyme called galactocerebrosidase (also called GALC). This enzyme normally breaks down certain fats in the body. People with Krabbe disease either don’t produce enough of this enzyme or produce an enzyme that doesn’t work properly.^[4] This test is typically performed on a blood sample. When the enzyme activity is severely reduced or absent, it strongly indicates Krabbe disease.

The enzyme test is particularly valuable because it provides clear biochemical evidence of the condition. However, doctors must interpret the results carefully, because some people with low enzyme activity may never develop symptoms or may develop symptoms much later in life. The amount of enzyme activity doesn’t always predict exactly how severe the disease will be or when symptoms will start.^[4]

Genetic Testing

Genetic testing examines the GALC gene, which provides instructions for making the galactocerebrosidase enzyme. Scientists have identified about 200 different mutations—changes in the genetic code—that can cause Krabbe disease.^[4] A genetic test looks for these mutations in a person’s DNA, which can be obtained from blood, saliva, or other tissue samples.

This type of testing serves multiple purposes beyond just confirming a diagnosis. It helps identify exactly which genetic changes a person has, which can sometimes provide information about disease prognosis. Genetic testing also identifies carrier status in family members, which is valuable information for parents considering future pregnancies. If both parents are known carriers, prenatal testing using techniques like amniocentesis or chorionic villus sampling can determine whether a developing baby has inherited both abnormal genes.^[4]

Imaging Studies

Brain imaging helps doctors see the physical changes that Krabbe disease causes in the nervous system. Magnetic resonance imaging (MRI) is the most commonly used imaging technique for Krabbe disease. This technology uses powerful magnets and radio waves to create detailed pictures of the brain’s internal structures.^[1]

In people with Krabbe disease, MRI scans typically show damage to the white matter of the brain. White matter consists of nerve fibers covered by myelin, the protective coating that gets destroyed in Krabbe disease. The MRI images reveal areas where this white matter has broken down, which helps confirm the diagnosis and assess how far the disease has progressed. Serial MRI scans over time can also show whether the disease is getting worse and how quickly changes are occurring.

Computed tomography (CT) scans, which use X-rays to create cross-sectional images of the brain, may also be used, though MRI generally provides more detailed information about white matter changes. Imaging studies are particularly helpful because they can show characteristic patterns of brain damage that distinguish Krabbe disease from other conditions affecting the nervous system.^[1]

Nerve Conduction Studies

Because Krabbe disease affects nerves throughout the body—not just in the brain—doctors may perform tests to measure how well signals travel through peripheral nerves. These studies, called electromyography (EMG) and nerve conduction studies, involve placing electrodes on the skin to measure the electrical activity of nerves and muscles.

In people with Krabbe disease, these tests often reveal slowed nerve signal transmission, which indicates damage to the myelin coating around peripheral nerves. This information helps doctors understand the full extent of nervous system involvement and can support the diagnosis when combined with other test results.^[1]

Cerebrospinal Fluid Analysis

Doctors may perform a lumbar puncture, also called a spinal tap, to collect cerebrospinal fluid (CSF)—the liquid that surrounds the brain and spinal cord. In people with Krabbe disease, the CSF often shows elevated protein levels, which reflects ongoing damage to the nervous system. While this finding isn’t specific enough to diagnose Krabbe disease on its own, it provides supporting evidence when considered alongside other test results.^[1]

Brain Biopsy

Although rarely necessary, a brain biopsy—removing a small sample of brain tissue for examination under a microscope—can definitively identify Krabbe disease. The hallmark finding is the presence of globoid cells, which are abnormally large cells that usually contain multiple nuclei. These cells form when certain white blood cells try to clean up the accumulated fats that the body cannot break down properly.^[4]

Brain biopsy is invasive and carries risks, so doctors typically reserve this procedure for cases where other diagnostic methods haven’t provided clear answers. In most situations, the combination of enzyme testing, genetic testing, and imaging provides sufficient information to make a confident diagnosis without needing a biopsy.

Diagnostics for Clinical Trial Qualification

When families consider enrolling their child in a clinical trial testing new treatments for Krabbe disease, they encounter an additional layer of diagnostic testing beyond what’s needed for standard diagnosis. Clinical trials have strict criteria about who can participate, and these requirements ensure that researchers can accurately measure whether experimental treatments work.

Enzyme activity testing remains central to clinical trial enrollment. Researchers typically require documentation that a participant’s galactocerebrosidase enzyme activity falls below a specific threshold. This ensures that everyone in the study actually has the biochemical deficiency that characterizes Krabbe disease. Some trials may specify the exact laboratory methods that must be used to measure enzyme activity to maintain consistency across all participants.^[4]

Genetic confirmation usually represents another prerequisite for clinical trial participation. Trial protocols often require genetic testing that identifies specific mutations in the GALC gene. This genetic information helps researchers understand whether different mutations respond differently to experimental treatments. Some trials may only accept participants with certain genetic profiles, particularly if early research suggests that specific mutations might respond better to the treatment being studied.

Imaging studies take on heightened importance in clinical trial settings. Baseline MRI scans performed before treatment begins establish a starting point for measuring changes. Researchers use standardized imaging protocols and specialized analysis techniques to quantify the extent of white matter damage with precision. Throughout the trial, participants undergo repeat MRI scans at specified intervals so researchers can objectively measure whether the experimental treatment slows, stops, or reverses brain damage.^[1]

Clinical trials also typically require comprehensive neurological assessments to document the participant’s functional status at the study’s start. These assessments might include detailed evaluations of motor skills, cognitive function, vision, hearing, and overall development. For infants, this means documenting which developmental milestones they have achieved. For older individuals, assessments might focus on specific abilities like walking, communication, or daily living skills. Researchers use standardized rating scales and measurement tools to ensure that they can reliably detect changes over time.

Many trials exclude participants who have already developed advanced symptoms or severe neurological damage, based on the premise that experimental treatments may work best when started early. For infantile Krabbe disease trials, this often means accepting only babies identified through newborn screening who haven’t yet developed symptoms, or babies with very early, mild symptoms. Specific clinical trial protocols define exactly which symptoms disqualify participation and how severe symptoms can be while still meeting enrollment criteria.^[14]

Blood tests beyond enzyme measurement often form part of clinical trial screening. These tests assess overall health, liver and kidney function, blood cell counts, and immune system status. Such information helps researchers identify participants who might face higher risks from experimental treatments and ensures that other health conditions won’t interfere with measuring the trial’s outcomes.

⚠️ Important

Clinical trials may require diagnostic testing at specialized centers or using specific laboratory methods. Families interested in clinical trials should discuss testing requirements with trial coordinators early in the process, as obtaining the right tests from approved laboratories may take time. Some trials cover the costs of required testing, while others may not, so families should clarify financial arrangements before proceeding.^[14]

Some clinical trials investigating treatments like stem cell transplantation require additional specialized testing to identify suitable donors and ensure that participants can safely undergo the transplant procedure. This might include tissue typing tests to match donors with recipients, heart function tests, lung function tests, and assessments of other organ systems that could be affected by intensive treatment protocols.

Throughout clinical trial participation, diagnostic testing continues beyond the initial screening phase. Follow-up tests occur at regular intervals to monitor safety and effectiveness. Participants might undergo repeated enzyme measurements, imaging studies, neurological assessments, and laboratory tests for months or years after receiving experimental treatment. This ongoing monitoring generates the data that researchers need to determine whether new treatments offer meaningful benefits.

The diagnostic criteria for clinical trial enrollment reflect the reality that researchers must carefully control variables to generate reliable data. While these strict requirements may feel frustrating to families hoping to access experimental treatments, they serve an important purpose in advancing scientific understanding and eventually bringing effective therapies to everyone affected by Krabbe disease.

Prognosis and Survival Rate

Prognosis

The outlook for individuals with Krabbe disease depends heavily on when symptoms first appear. Babies with the infantile form, which accounts for about 85 to 90 percent of all Krabbe disease cases and begins before 12 months of age, face the most challenging prognosis. These infants typically experience rapid neurological deterioration once symptoms start. Without treatment, the disease progresses quickly through multiple stages—starting with irritability and feeding difficulties, advancing to vision loss and developmental regression, and ultimately resulting in severe disability.^[1] The condition is degenerative, meaning it continuously worsens over time as more nerve cells lose their protective myelin coating and stop functioning properly.

Some babies identified through newborn screening before symptoms develop may benefit from early intervention with treatments like stem cell transplantation. These infants have a better prognosis than those diagnosed after symptoms appear, though they still face significant challenges. Early treatment may slow disease progression and extend survival, but it typically does not prevent all neurological problems. Children treated early may retain some developmental skills and quality of life that would otherwise be lost, though they often still experience progressive difficulties including developmental delays, muscle weakness, vision problems, and other complications.^[14]

Individuals with later-onset forms of Krabbe disease—those whose symptoms begin after the first year of life—generally have a more favorable prognosis than those with infantile disease. These individuals typically survive longer and experience slower disease progression. However, they still face progressive neurological decline that significantly impacts their quality of life, including loss of mobility, vision problems, cognitive impairment, and other serious complications.^[1]

Survival Rate

For babies with untreated infantile Krabbe disease, survival is severely limited. Most children with this form who do not receive treatment die before reaching two years of age, with many not surviving past their second birthday.^[1] Research indicates that for those with early infantile disease, one-year, two-year, and three-year survival rates are approximately 60 percent, 26 percent, and 14 percent respectively.^[3]

Babies who receive stem cell transplantation before developing symptoms may experience extended survival, though mortality associated with the transplantation procedure itself occurs in about 15 percent of cases.^[14] Long-term survival data for treated infants continues to accumulate, showing that some children live well beyond early childhood when treated early, though they typically still face ongoing neurological challenges.

Individuals with late-onset forms of Krabbe disease survive significantly longer than those with infantile disease. Some live many years after their symptoms begin, though the exact survival time varies considerably depending on the age at onset, the specific genetic mutations involved, and the rate of disease progression.^[1] However, even with longer survival, these individuals experience progressive disability and declining quality of life as the disease advances.

#1 Clinical Trials Search in Europe